These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35530142)

  • 21. Concentration-Induced J-Aggregate Formation Causes a Biphasic Change in the Release of trans-Combretastatin A4 Disodium Phosphate from Archaeosomes and the Subsequent Cytotoxicity on Mammary Cancer Cells.
    Daswani VP; Ayesa U; Venegas B; Chong PL
    Mol Pharm; 2015 Oct; 12(10):3724-34. PubMed ID: 26355665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifunctional Theranostic Liposomes Loaded with a Hypoxia-Activated Prodrug for Cascade-Activated Tumor Selective Combination Therapy.
    Dai Y; Wang B; Sun Z; Cheng J; Zhao H; Wu K; Sun P; Shen Q; Li M; Fan Q
    ACS Appl Mater Interfaces; 2019 Oct; 11(43):39410-39423. PubMed ID: 31578854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synchronous delivery of oxygen and photosensitizer for alleviation of hypoxia tumor microenvironment and dramatically enhanced photodynamic therapy.
    Guo X; Qu J; Zhu C; Li W; Luo L; Yang J; Yin X; Li Q; Du Y; Chen D; Qiu Y; Lou Y; You J
    Drug Deliv; 2018 Nov; 25(1):585-599. PubMed ID: 29461122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
    Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
    Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
    Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
    Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
    Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
    Badn W; Kalliomäki S; Widegren B; Sjögren HO
    Clin Cancer Res; 2006 Aug; 12(15):4714-9. PubMed ID: 16899622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme-triggered deep tumor penetration of a dual-drug nanomedicine enables an enhanced cancer combination therapy.
    Gu L; Duan Z; Li X; Li X; Li Y; Li X; Xu G; Gao P; Zhang H; Gu Z; Chen J; Gong Q; Luo K
    Bioact Mater; 2023 Aug; 26():102-115. PubMed ID: 36875053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction of a nanotheranostic system Zr-MOF@PPa/AF@PEG for improved photodynamic therapy effects based on the PDT‑oxygen consumption and hypoxia sensitive chemotherapeutic drug.
    Wang X; Wang Z; Ma W; Wu X; Fang W; Guo C; Jin Y
    J Photochem Photobiol B; 2021 Sep; 222():112274. PubMed ID: 34330082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pure photosensitizer-driven nanoassembly with core-matched PEGylation for imaging-guided photodynamic therapy.
    Zhang S; Wang Y; Kong Z; Zhang X; Sun B; Yu H; Chen Q; Luo C; Sun J; He Z
    Acta Pharm Sin B; 2021 Nov; 11(11):3636-3647. PubMed ID: 34900542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
    Nathan P; Zweifel M; Padhani AR; Koh DM; Ng M; Collins DJ; Harris A; Carden C; Smythe J; Fisher N; Taylor NJ; Stirling JJ; Lu SP; Leach MO; Rustin GJ; Judson I
    Clin Cancer Res; 2012 Jun; 18(12):3428-39. PubMed ID: 22645052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
    Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
    Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.
    Liu Y; Yin T; Keyzer F; Feng Y; Chen F; Liu J; Song S; Yu J; Vandecaveye V; Swinnen J; Bormans G; Himmelreich U; Oyen R; Zhang J; Huang G; Ni Y
    Oncotarget; 2017 Aug; 8(33):55204-55215. PubMed ID: 28903414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioorthogonal chemistry and illumination controlled programmed size-changeable nanomedicine for synergistic photodynamic and hypoxia-activated therapy.
    Jiang M; Liu Y; Dong Y; Wang K; Yuan Y
    Biomaterials; 2022 May; 284():121480. PubMed ID: 35390710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
    Liu L; Mason RP; Gimi B
    Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.
    Welford AF; Biziato D; Coffelt SB; Nucera S; Fisher M; Pucci F; Di Serio C; Naldini L; De Palma M; Tozer GM; Lewis CE
    J Clin Invest; 2011 May; 121(5):1969-73. PubMed ID: 21490397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
    Shen Y; Wu L; Qiu L
    J Pharm Sci; 2017 Oct; 106(10):3076-3083. PubMed ID: 28619603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomimetic Decoy Inhibits Tumor Growth and Lung Metastasis by Reversing the Drawbacks of Sonodynamic Therapy.
    Zhao H; Zhao B; Li L; Ding K; Xiao H; Zheng C; Sun L; Zhang Z; Wang L
    Adv Healthc Mater; 2020 Jan; 9(1):e1901335. PubMed ID: 31762228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.